RegeneRx Biopharmaceuticals, Inc.
RegeneRx is dedicated to the healing of chronic wounds caused by disease, abrasion, or other pathology.
The company was founded in 1982 by Dr. Allan L. Goldstein, Professor and Chairman of Biochemistry and Molecular Biology at The George Washington University Medical School in Washington, D.C. In 2001, RegeneRx (OTCBB:RGRX) received an exclusive worldwide license from NIH relating to all intellectual property covered under the patent applications related to Tß4.
J.J. Finkelstein, President and CEO
Allan L. Goldstein, PhD, Chief Scientific Advisor
David Crockford, VP, Clinical and Regulatory Affairs
C. Neil Lyons, CPA, CFO and Treasurer
Allan L. Goldstein, Ph.D., Chairman
J.J. Finkelstein
Mauro Bove
Richard J. Hindin
Joseph C. McNay
Albert Rosenfeld
L. Thompson Bowles, M.D., Ph.D.
3 Bethesda Metro Center
Suite 630
Bethesda, MD 20814
USA
Phone: +1-301-280-1992
Fax: +1-301-280-1996
Thymosin beta 4 (Tß4), which originates from the thymus, is a multi-functional compound that plays a vital role in the regeneration, remodelling and healing of injured or damaged tissues. It is known to play a pivotal role in a variety of immune, cellular, and physiological processes including: regulation of actin polymerisation, regulation of stem cell proliferation, angiogenesis and anti-inflammation. Tß4’s effectiveness in healing wounds was confirmed in animal studies.
Phase II clinical trial to test thymosin beta 4 (Tß4) for the treatment of chronic pressure ulcers started in November 2004. A second Phase II clinical trial to test thymosin beta 4 (Tß4) for the treatment of venous stasis ulcers commenced in January 2005. And in a third Phase II clinical trial thymosin beta 4 (Tß4) is tested for the treatment of patients with epidermolysis bullosa (EB).
The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.
Related patents
- Treatment of Infections and Other Disorders
- Treatment of Infections and Other Disorders
- Treating Epidermlyosis Bullosa with Thymosin Beta 4
- Treatment of Infections and Other Disorders
- Treatment of Infections and Other Disorders
- Method Treating or Preventing Respiratory Microbial Infection of Respiratory Tissue
- Method Treating or Preventing Microbial Eye Infection
- Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Neuro-, Muscular- or Neuro-muscular-degenerative Disease, or Restore Tissue Adversely Affected by Said Disease
- Compositions and Methods for Delivering Thymosin Beta 4, Analogues, Isoforms and Other Derivatives
- Treatment or Prevention of Damage Due to Radiation Exposure
- Treatment or Prevention of Damage Due to Radiation Exposure
- Compositions and Methods for Delivering Thymosin Beta 4, Analogues, Isoforms and Other Derivatives
- Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin B4 (TB4), Analogues, Isoforms and Other Derivatives
- Method of Treating or Preventing Biological or Immunological Responses to a Reactive Chemical or Biological or Toxic Agent
- Treatment of Skin, and Wound Repair, with Thymosin Beta 4
- Treatment of Skin, and Wound Repair, with Thymosin Beta 4
- Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Cogestive Heart Failure
- Method of Treating or Preventing Tissue Deterioration, Injury or Damage Due to Hyperthrophic Muscle Disease
- Methods and Compositions for Decreasing Cohesivity of Pathological Respiratory Tract Secretions
- Treating or Preventing Extracellular Matrix Build-up
- Method of Treating or Preventing Tissue Damage Caused by Increased Blood Flow
- Inhibition or Reversal of Skin Aging by Actin-sequestering Peptides
- Method of Treating Disorders of the Eye and Surrounding Tissue with Thymosin ss4 (Tss4), Analogues, Isoforms and Other Derivates
- Methods of Treating Epidermolysis Bullosa and Associated Dermatological Indications with Thymosin Beta 4, Analogues, Isoforms and Other Derivatives
- Compositions and Methods for Delivering Thymosin Beta 4, Analogues, Isoforms and Other Derivates
- Method for Detecting Development of a Physiological Disorder in a Subject
- Treatment or prevention of damage due to radiationexposure
- Treating Epidermlyosis Bullosa with Thymosin Beta-4
- Treatment of infections and other disorders
- Method of Healing or Preventing Inflammation, Damage and Other Changes that Occur Prior to, During or Immediately after a Myocardial Event with Thymosin Beta 4, Analogues, Isoformes and Other Derivates
- Method of Treating or Preventing Biological or Immunological Responses to a Reactive Chemical or Biological or Toxic Agent
Related news
- RegeneRx Receives First Ophthalmic Wound-healing Patent in China
- RegeneRx President and CEO to Speak at BIO InvestorForum 2007
- RegeneRx Receives U.S. Patent for Wound Healing Technology
- RegeneRx Biopharmaceuticals, Inc. Updates Clinical Trials Program
- RegeneRx to Present at the 20th Annual Symposium On Advanced Wound Care
- RegeneRx Receives First Patent for Preventing and Repairing Damage to Cardiac Tissue Before, During and After Injury
- RegeneRx Receives First Patent for Treating Wounds and Other Disorders of the Eye
- Researchers Find RegeneRx's TB4 Inhibits Activation of Key Inflammatory Molecule - NFkB
- RegeneRx Raises $9.55 Million in Private Placement
- RegeneRx Receives Australian Patent for Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides
- Researchers Find RegeneRx's TB4 Prevents Cell Death Caused by Common Eye Drop Preservative; TB4 Prevents BAK-mediated Apoptosis in Human Corneal and Conjunctival Epithelial Cells
- RegeneRx to Present at Biotechnology Industry Organization's 2006 Business Forum
- RegeneRx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year End Earnings Release and Conference Call
- RegeneRx Closes $7.3 Million Offering of Common Stock
- RegeneRx's Chief Executive Interviewed by Wall Street Transcript For Annual Biotechnology Issue
- RegeneRx Adds L. Thompson Bowles, M.D., Ph.D. To Board of Directors
- RegeneRx Enters Research Collaboration to Study Protective Effects of TB4 on Degenerative Muscle Disease and Cardiomyopathy
- Key European Patent Granted for RegeneRx's Wound Healing Technology
- RegeneRx Receives $5 Million Equity Investment
- RegeneRx Names Chief Financial Officer
- RegeneRx Closes on First Tranche of $5.86 Million Private Placement
- RegeneRx Files with FDA for Phase II Clinical Trial for Chronic Pressure Ulcers